加拿大Microbix Biosystems  www.microbix.com
加拿大Microbix Biosystems成立于1988年,是世界頂尖生物技術(shù)公司，其流感疫苗生產(chǎn)技術(shù)具有世界一流水平。提供最具性價(jià)比的傳染病診斷產(chǎn)品，如TORCH，衣原體，流感抗原
Microbix specializes in developing proprietary biological technologies, which have lead to the development of a pipeline of products in three areas; Biotherapeutics, vaccines and non-therapeutic biologics. The Company selects products for development based on potential near term market opportunity that will provide above average returns in a high margin business. Products in Microbix pipeline generally have limited regulatory barriers or no regulatory requirement at all before reaching the market.
Microbix was founded in 1988 and created Microbix Virology (Since renamed Microbix Core Base Business) which was to commercialize, develop and manufacture infectious disease antigens for medical diagnostic tests for major multinational manufacturers. While the Company has successfully commercialized over 60 products, it was recognized early that the Company could not reach its long-term revenue and profit objectives in this area alone. However, Microbix Core Base Business is profitable and generates a positive cash flow that has been used to finance its high value product pipeline. The Company's pipeline includes large market protein drugs and a proprietary vaccine technology platform. These products are either in licensing discussions or have been licensed.
Microbix Core Base Business was the basis of the technology platform Microbix has built over the years, based on cell culture, virology, protein expression, purification and characterization, from which it develops its potential lucrative products. The Company licenses its products and proprietary technologies to large global firms with franchises in target markets. Microbix transfers licensed products to these firms in exchange for a combination of substantial royalties, upfront payments and financing for all costs to market launch. Revenue from royalties has no associated cost.